Try our Advanced Search for more refined results
Hill et al v. Accentia Biopharmaceuticals, Inc. et al
Case Number:
8:13-cv-01945
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
-
February 04, 2015
$1.25M Accentia Shareholder Settlement Wins Green Light
A Florida federal judge signed off Wednesday on a $1.25 million settlement that ends a class action brought by stockholders of Accentia Biopharmaceuticals Inc. and a subsidiary accusing the companies of lying to investors about the performance of a non-Hodgkin's lymphoma treatment vaccine in development.
-
September 05, 2014
Accentia Strikes $1.25M Deal To End Investors' Vaccine Suit
An Accentia Biopharmaceuticals Inc. subsidiary agreed Friday to pay $1.25 million to settle a putative securities class action in Florida federal court accusing the company of lying to investors about the performance of a non-Hodgkin's lymphoma treatment vaccine in development that artificially inflated both companies' stock prices.
-
July 29, 2013
Accentia Faces Investor Suit Over Lymphoma Vaccine
The directors of Accentia Biopharmaceuticals Inc. subsidiary Biovest International Inc. lied to investors about the performance of a non-Hodgkin's lymphoma treatment vaccine that Biovest was developing, artificially inflating the companies' stock prices, according to a securities class action filed Friday in Florida federal court.